Jardiance® reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25% in adults with and without diabetes who had heart failure with reduced ejection fraction

- Jardiance (empagliflozin) also significantly reduced the relative risk of first and recurrent hospitalization for heart failure by 30% and significantly slowed kidney function decline - Results were consistent in subgroups with and without type 2 diabetes - Heart failure is the leading cause of